The first HDAC inhibitors approved for use in treating cutaneous T cell lymphoma (CTCL) were vorinostat (SAHA) and romidepsin255 (Table 1). The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.